

NORTHWEST AIDS EDUCATION AND TRAINING CENTER

Cervical Cancer Screening in HIV

Hillary Liss, MD Harborview Medical Center, Madison and Adult Medicine Clinics NW AETC, Medical Program Director

Presentation prepared by: Hillary Liss Last Updated: December 5, 2012



Outline

- Epidemiology of HPV and cervical cancer in HIV
- Review of cervical anatomy and HPV pathophysiology
- Current cervical cancer screening guidelines
 - When to start
 - When to stop
 - What to order and how often
 - What to do after hysterectomy
 - Role of HPV testing
 - Special populations
- Follow-up of abnormal cytology
- Future directions in cervical cancer screening





Epidemiology of HPV and Cervical Cancer in HIV



HPV Epidemiology

- 5th most common cancer in humans
- 2nd most common cancer in women
- 190,000 women die each year world wide
 - 78% in resource poor settings, still the leading cause of death from cancer for women
- Up to 50% of sexually active women in the US HPV+ 36 months after coitarche
 - Prevalence of ~57% in sexually active adolescent women
 - Resolution of infection occurs in 90% of adolescents in 2y
- Women 50 years of age: 80% will have acquired genital HPV infection
- 1. Cates W, Sex Transm Dis, 1999.
- 2. Weinstock H, Perspect Sex Reprod Health, 2004.
- 3. Am J Epi, 2003;157:218.



Human Papilloma Virus (HPV)

- Most common sexually acquired infection in the world
- DNA tumor virus
- Intraepithelial infection
- > 100 types
 - 40 infect cervix
 - 13 oncogenic (16, 18, 31, 33...) → cancer
 - 6, 11 \rightarrow genital warts
- Recurrent infections common
- Available prevention: HPV vaccine and CONDOMS!

CDC Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-infected adults and adolescents, *MMWR*, 2009.



HPV and HIV

- HPV is more persistent in HIV positive women
- Higher levels of HPV are detected in HIV positive women
- Multiple HPV infections are more common
- The incidence rate of cervical cancer is still up to 9 times more likely in women with HIV
- Cervical cancer → AIDS-defining condition
- Cervical dysplasia → "B" condition

Sun XW, *NEJM*, 1997. Jamieson DJ, *AJOG*, 2012. Mbulaiteye SM, *J Acquir Immune Defic Syndr*, 2003.



HPV Manifestations

- Persistent HPV infection can lead to:
 - Warts
 - Genital
 - Anal
 - Oral
 - Cancer precursors
 - CIN
 - VIN
 - VAIN
 - AIN
 - Cancer (squamous and adenocarcinoma)
 - Cervix
 - Vulva
 - Vagina
 - Oral cavity
 - Penis
 - Oropharynx



HPV and Cancer, US Rates 2004-2008

Site	Average #/yr	% HPV related	Range
Cervix	11967	96	95-97
Vulva	3136	51	37-65
Vagina	729	51	37-65
Anus-female	3089	93	86-97
Anus-male	1678	93	86-97
Oral-female	2370	63	50-75
Oral-male	9356	63	50-75



Gillison, Cancer 2008; 113: 3036-46




Review of Cervical Anatomy and HPV Pathophysiology




Definitions and Anatomy

- Pre-pubescent cervix covered with columnar epithelium
- Columnar cells gradually replaced by squamous epithelium (squamous metaplasia)
- Squamocolumnar junction: intersection between columnar and squamous epithelium
- Transformation Zone: the area of squamous metaplasia
 - Most common location of neoplastic change
 - Important landmark for colposcopy






Normal Cervix





http://screening.iarc.fr/colpo.php

HPV Natural History



The Three Steps of Cervical Carcinogenesis.

The steps can be conceptualized as infection with specific high-risk types of human papillomavirus (HPV), progression to a precancerous lesion, and invasion. HPV infections are usually transient and are often associated with mild cytologic abnormalities. Persistent infection with high-risk types of HPV is uncommon and is required for progression.



Wright, NEJM 2003; 348(6):489-490.



Current Cervical Cancer Screening Guidelines



Different Guidelines: Different Functions

- USPSTF/ACS/ASCCP/ASCP→ age, interval and frequency of screening (updated March 2012)
- ASCCP Consensus Guidelines → interpretation and management of screening and colposcopy results (updated 2006, minor changes March 2012)
- IDSA/CDC/HHS OI Guidelines→ both (updated 2009)
- Ultimate goal of all guidelines is cervical cancer prevention via:
 - Screening (cytology with or without HPV DNA testing)
 - Evaluation of screen positive women using colposcopy and biopsy
 - Treatment of women with biopsy-confirmed high-grade cancer precursors



Frequency of Screening in HIV

- Pap smear twice in the first year after diagnosis or entry into care
 - If both Pap smears are normal, then annual screening with Pap
 - If abnormal, follow-up will depend on the abnormality
- Refer to colposcopy if:
 - ASCUS (Atypical squamous cells of undetermined significance)
 - ASC-H (Atypical squamous cells cannot exclude high grade)
 - AGC (Atypical glandular cells)
 - LSIL (Low grade squamous intraepithelial lesion)
 - HSIL (High grade squamous intraepithelial lesion)

CDC Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-infected adults and adolescents, *MMWR*, 2009.



Cervical Cancer Screening Guidelines

	USPSTF/ACS/ASCCP (WOMEN WITHOUT HIV)	WOMEN WITH HIV	
AGE AT INITIATION	21 regardless of risk factors	Onset of sexual activity	
FREQUENCY			
Age 21-29	Pap every 3 years	Annually	
Age ≥30	Pap every 3 years <u>OR</u> Pap + HPV every 5 years	Annually	
DISCONTINUATION	Age 65	?????? Never ??????	
s/p HYSTERECTOMY	D/C if for benign reasons and no history of CIN 2+ for 20 years, otherwise screen for 20 years after	?????? Same ??????	
HPV VACCINATED	No change	No change	
Moyer VA, <i>Ann Intern Med</i> , 2012. CDC Guidelines for Prevention and T	₩ TC ech●		

in HIV-infected adults and adolescents, MMWR, 2009.


Screening of Adolescents with HIV

- Symposium sponsored by NIH/ACS/ASCCP in 2009 to address adolescents
- Less is more approach
 - Start screening at age 21 regardless of risk factors
 - Never use HPV testing in adolescents
 - Rarely intervene with colposcopy or LEEP/CONE except HSIL, CIN3
 - Rationale: increased risk of pre-term delivery and LBW infants, psycho-sexual dysfunction, high rates of regression even with CIN 2,3
- But in HIV, regression rates are lower, more CIN
 - Start screening right away at onset of sexual activity
 - Any abnormality, ASCUS+ \rightarrow colposcopy
 - Reserve treatment for CIN3
 - No role for HPV testing





Oops, I ordered HPV and it's Positive





Role for HPV Testing

General Population

- Triage ASCUS result
- Co-test with $Pap \ge 30 y$
- Post-menopausal women LSIL
- Follow-up after colpo or treatment procedure (LEEP/CONE) per guidelines


HIV Population

- Triage ASCUS result?
- Co-test with Pap \ge 30 y
- Post-menopausal women
 LSIL
- Follow-up after colpo or treatment procedure (LEEP/CONE) per ASCCP guidelines?
- Per CDC OI Guidelines: NEVER!

Centers for Disease Control and Prevention. Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents. MMWR 2009;58 (No. RR-4) April 10, 2009




Pap Smear Results



2006 Consensus Guidelines www.asccp.org

Pap Smear Results





Triage of ASCUS Results

- Conflicting guidelines
 - 2006 ASCCP Guidelines
 - CDC OI Guidelines
- ASCUS common in HIV, up to 78% in 4-5 year follow-up
- ASCCP: HIV infected women with ASCUS can be triaged as uninfected women
 - UNLESS severely immunocompromised?
- CDC: Never use HPV, data insufficient in this population



ASCCP Algorithm for ASCUS Management

HPV DNA Testing* Repeat Cytology Preferred if liquid-based cytology @ 6 & 12 mos or co-collection available **HPV Positive*** **HPV Negative** Both Tests > ASC Negative (on either result) (managed in same manner as Colposcopy women with LSIL) Endocervical sampling preferred in women Repeat Cytology with no lesions, and those with Routine @ 12 mos unsatisfactory colposcopy Screening NO CIN CIN Manage per **ASCCP** Guideline **HPV Unknown** HPV Positive* Repeat Cytology Cytology Repeat Colposcopy @ 6 & 12 mos OR @ 12 mos HPV DNA Testing **Routine Screening** Negative @ 12 mos

Management of Women with Atypical Squamous Cells of Undetermined Significance (ASC-US)

Copyright 2006, 2007, American Society for Colposcopy and Cervical Pathology. All rights reserved.

* Test only for high-risk (oncogenic) types of HPV




http://www.asccp.org/ConsensusGuidelines/ConsensusGuidelinesOverview/tabid/ 5956/Default.aspx

Management of the Pregnant Woman

- Want to avoid invasive intervention in pregnant women
- Only finding that would affect management, timing, route of delivery is invasive cancer
- Can defer colposcopy for ASCUS and LSIL until 6 weeks post-partum
- Immediate colposcopy for HSIL or AGC

www.asccp.org








Follow-up of Abnormal Screening



Goal of Colposcopy

- Localize the Transitional Zone (squamo-columnar junction)
- Evaluate the extent of the disease with application of acetic acid
- Locate the area most suspicious for biopsy
- Determine if invasive cancer is
 present






Vazquez E. General Principles of Colposcopy, Residents Academic Day 7/22/2010 #7





ASCCP Algorithms

- Available at ASCCP website
 - <u>http://www.asccp.org/LinkClick.aspx?fileticket=FRKDC1RPF7A</u> <u>%3d&tabid=5965</u>
- Not specifically for women with HIV, but very similar to the OI Guidelines with the exception of HPV testing






www.asccp.org

Strategies for Improving Screening Rates

- Patient education addressing rationale and importance of Pap smears for women living with HIV
 - Face-to-face
 - Public Health materials in multiple languages
- Ask about specific concerns and normalize fear and embarrassment
- Offer options for a female clinician if patient uncomfortable with male provider, if possible
- Reminder notices, systemic ticklers
- Coordination of care with GYN





Possible Future Directions

- Role for HPV testing in women with HIV?
 - Increase interval for testing
- HPV Vaccine efficacy data in women with HIV
- New HPV vaccines
 - 9 valent, predicted to cover 85% of HPV infections (current 70%)
- More specific HPV tests for infection (DNA methylation)
- Anal Pap guidelines
 - Women with HIV, CIN3 likely candidates for screening
- Better financial coverage for HPV co-testing
 - Again not currently recommended in HIV



Take-Home Points

- Abnormal cervical cytology is more common among HIV-infected women
- Early diagnosis and treatment can be achieved only by routine screening, ideally as part of primary care
- Complete pelvic exam needed to evaluate for uterine, vaginal, and vulvar abnormalities, as well as vaginitis, condyloma, HSV and other STDs
- At this time, annual Pap smears are the standard of care
- Role of HPV testing is limited in women with HIV
 - Triage of women with ASCUS?
 - Follow-up after colposcopy?
- Be aware of and address cultural/individual factors that may be interfering with screening
- Refer to colposcopy for results of ASCUS (+/- HPV?) or worse



Resources

- ACS/ASCCP/ASCP Screening Guidelines
 - http://onlinelibrary.wiley.com/doi/10.3322/caac.21139/abstract
- USPSTF Screening Guidelines
 - http://www.uspreventiveservicestaskforce.org/uspstf/uspscerv.htm
- Adult and Adolescent OI Guidelines, pages 68-75
 - http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi_041009.pdf
- American Society for Colposcopy and Cervical Pathology (ASCCP) Guidelines
 - www.asccp.org
- HRSA A Guide to the Clinical Care of Women with HIV/AIDS
 - www.hab.hrsa.gov
- Adolescent Guidelines and Rationale
 - http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058950/

